T cells have long held the title of the ideal immune cells for CAR therapy, but recent discoveries are opening new possibilities for other immune cells.
A team of industry and academic researchers developed a new way to engineer the immune
system, leading to the first clinical trial using genetically modified macrophages.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.